Contrasting Metagenomi (MGX) and Its Peers

Metagenomi (NASDAQ:MGX) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Metagenomi to related companies based on the strength of its earnings, valuation, risk, profitability, analyst recommendations, dividends and institutional ownership.

Institutional & Insider Ownership

47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Metagenomi and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Metagenomi	$13.56 million	-$87.87 million	-0.29
Metagenomi Competitors	$697.88 million	$11.96 million	-10.91

Metagenomi’s rivals have higher revenue and earnings than Metagenomi. Metagenomi is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings for Metagenomi and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1	0	2	0	2.33
Metagenomi Competitors	9793	15079	45386	1576	2.54

Metagenomi currently has a consensus target price of $6.00, suggesting a potential upside of 723.05%. As a group, “Biotechnology” companies have a potential upside of 102.86%. Given Metagenomi’s higher probable upside, research analysts clearly believe Metagenomi is more favorable than its rivals.

Risk and Volatility

Metagenomi has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Metagenomi’s rivals have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.

Profitability

This table compares Metagenomi and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
Metagenomi Competitors	-12,359.35%	-203.09%	-30.93%

Summary

Metagenomi rivals beat Metagenomi on 8 of the 13 factors compared.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.